Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? (Q73134065)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10542390%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

title

Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10542390%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author name string

Duncan R

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10542390%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 November 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10542390%20AND%20SRC:MED&resulttype=core&format=json

Pharmaceutical science & technology today

1 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10542390%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10542390%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10542390%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

441-449

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10542390%20AND%20SRC:MED&resulttype=core&format=json

Stealth® liposomes: from theory to product

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Drug-polymer conjugates: potential for improved chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Is there a future for cancer chemotherapy? The Michel Clavel Lecture

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

1 reference

7 January 2021

Control of the cell cycle and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

1 reference

7 January 2021

Antisense therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Gene directed enzyme prodrug therapy for cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Prolonged suppression of rat testis function by a depot formulation of Zoladex, a GnRH agonist

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

The next frontier of molecular medicine: delivery of therapeutics.

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Vascular Endothelium as the Vulnerable Element in Tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Angiostatin induces and sustains dormancy of human primary tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Delivery of novel therapeutic agents in tumors: physiological barriers and strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

The pharmacology of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues.

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Delivery of molecular and cellular medicine to solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Targeting of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate to the hepatocyte galactose-receptor in mice: visualisation and quantification by gamma scintigraphy as a basis for clinical targeting studies

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Gamma scintigraphy of the biodistribution of 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Development of targeted delivery systems for nucleic acid drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

DNA complexes with block and graft copolymers of N-(2-hydroxypropyl)methacrylamide and 2-(trimethylammonio)ethyl methacrylate.

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Gene transfer with lipospermines and polyethylenimines

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD).

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

A phase II study of DaunoXome in advanced urothelial transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900211-4

7 January 2021

10.1016/S1461-5347(99)00211-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10542390%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference